London, UK – The global pharmaceutical industry stands at a critical juncture, facing an unprecedented era of policy and regulatory shifts that are fundamentally reshaping commercial strategies and R&D pipelines. A comprehensive survey of 175 pharma executives, conducted by business management consultancy Numerof & Associates, reveals a growing reluctance to launch high-priced, specialty products in what are now perceived as "lower-value" markets outside the United States. This strategic pivot is driven by an intense focus on a drug’s demonstrable clinical and economic value, alongside a heightened demand for real-world evidence (RWE) to justify pricing and reimbursement decisions.
n
The findings underscore a dramatic departure from historical operating models, as companies are compelled to consider the cascading effects of market access and pricing decisions across international borders. Executives describe the current policy environment as "unlike anything" they have previously experienced, necessitating a complete re-evaluation of how pharmaceutical innovation is brought to patients worldwide.
n
An Unprecedented Policy Storm Reshapes Pharma’s Global Strategy
n
The pharmaceutical landscape has long been influenced by national policies, but recent legislative actions and proposed regulations are creating a more interconnected and complex web of considerations for drug manufacturers. The Numerof & Associates report, based on interview-led conversations with high-ranking individuals from 67 small, medium, and large-cap pharmaceutical companies, paints a vivid picture of an industry grappling with profound uncertainty and strategic recalibration.
n
The Numerof & Associates Revelation: A Strategic Retreat
n
At the heart of the report’s revelations is the stark observation that pharmaceutical companies are increasingly scrutinizing the commercial viability of launching new, often high-cost, specialty therapies in markets where pricing potential is constrained. This hesitancy is not merely a tactical adjustment but a strategic re-orientation, driven by the realization that a single pricing decision in one market can have significant, irreversible repercussions on a product’s global commercial trajectory. The survey highlights a collective acknowledgment among executives that the era of independent, region-specific market strategies is rapidly drawing to a close.
n
"The industry is navigating uncharted waters," states the report, capturing the sentiment of executives who unanimously voiced the transformative nature of current policy changes. This new environment demands an industry-wide reconsideration of commercial approaches, placing market access at the forefront of executive considerations, rather than a downstream operational concern. The traditional model, where decisions were largely confined to specific regions, is being replaced by a more holistic, interconnected global perspective.
n
The Driving Forces: US Policy Shifts Cast a Long Shadow
n
Much of the impetus for this global reassessment originates from significant policy changes within the United States, a market traditionally seen as the primary engine for pharmaceutical innovation and revenue generation. Two pieces of legislation, in particular, loom large:
n
- n
- The Inflation Reduction Act (IRA): Enacted in August 2022, the IRA introduced provisions allowing Medicare to negotiate drug prices for the first time. While initially targeting a small number of high-cost drugs, its long-term implications are profound. Executives fear that negotiated prices in the US could set a de facto benchmark, influencing pricing expectations in other markets. Furthermore, the IRA’s inflation rebate provision, requiring manufacturers to pay rebates to Medicare if drug prices rise faster than inflation, adds another layer of financial complexity and risk to US market strategies. The very existence of government price negotiation in the largest pharmaceutical market forces companies to rethink their entire pricing philosophy.
- The Most Favored Nation (MFN) Provision (and its conceptual impact): Although a specific MFN rule, which would have linked US drug prices to the lowest prices in other developed countries, was blocked by courts, the idea behind it continues to exert influence. The ongoing debate and the potential for similar future policies mean that US pricing decisions are no longer made in isolation. Executives are acutely aware that a high US price could attract political scrutiny and potentially trigger calls for price referencing, while a lower price elsewhere could undermine their ability to command premium pricing in the US. This conceptual threat contributes significantly to the global pricing focus observed in the survey.
n
n
n
Europe’s Harmonizing Hand: Joint Clinical Assessment and the EU Pharmaceutical Package
n
Beyond the US, Europe is also experiencing a wave of policy reforms that further compel pharmaceutical companies to adopt a more integrated global strategy.
n
- n
- Joint Clinical Assessment (JCA): A cornerstone of the EU Health Technology Assessment (HTA) Regulation, the JCA aims to streamline the assessment of clinical evidence for new drugs across member states. While designed to reduce duplication and accelerate access, it also means that a single, unified clinical assessment will inform pricing and reimbursement negotiations across a significant portion of the European market. This shift demands a more robust and universally applicable evidence package from the outset, rather than tailoring evidence to individual national HTA bodies. The collective European voice in assessing a drug’s clinical value will inevitably strengthen its negotiating power.
- The EU Pharmaceutical Package: This comprehensive legislative proposal seeks to revise the entire pharmaceutical regulatory framework in the EU. Key elements include shortening regulatory protection periods for drugs unless certain conditions (like timely patient access across all member states) are met, and incentivizing innovation for unmet medical needs. This package further intertwines market access with regulatory approval, making it imperative for companies to demonstrate a clear strategy for broad European patient access from early development stages. The risk of reduced market exclusivity serves as a powerful incentive to consider launch sequencing and market penetration with greater care.
n
n
n
These interlocking policies, both in the US and Europe, are dismantling the traditional silos that once allowed companies to optimize pricing and market access strategies on a country-by-country basis. The current environment demands a comprehensive, globally aware approach, where a decision in one major market inevitably ripples across the entire portfolio.
n
Commercial Strategies Under Global Scrutiny
n
The new policy landscape has fundamentally altered how pharmaceutical companies approach the commercialization of their products, particularly high-priced specialty therapies. The survey highlights a shift from a reactive, country-specific market access approach to a proactive, globally integrated one.
n
Market Access: The New Gatekeeper of Value
n
Historically, market access considerations often came into play later in the drug development lifecycle, primarily focused on negotiating reimbursement after regulatory approval. However, the Numerof report unequivocally states that market access has now moved to the forefront of executive considerations. This means that from early-stage clinical development, companies are asking not just "Can we develop this drug?" but "Can we get this drug reimbursed at a sustainable price across our target markets?"
n
The increasing scrutiny around a drug’s clinical and economic value is central to this shift. Payers, health systems, and HTA bodies are demanding robust evidence that goes beyond mere clinical efficacy. They want to see clear demonstrations of cost-effectiveness, comparative efficacy against existing standards of care (SoC), and tangible patient-centric value. Without this comprehensive value proposition, justifying premium pricing becomes increasingly challenging, making market access a critical determinant of commercial success.
n
The Domino Effect of Global Pricing: Rethinking Launch Sequencing
n
One of the most significant changes identified by the survey is the profound impact on launch sequencing. In the past, companies might have strategically launched in smaller, lower-price markets first to gain initial market experience or fulfill early access programs. However, the current environment, with its interconnected pricing reference systems and the conceptual threat of policies like MFN, makes such a strategy increasingly risky.
n
"Companies are now thinking more about whether, and when, they should launch their drugs in individual countries due to the potential downstream impacts on pricing negotiations a drug’s debut may have in subsequent locations," the report notes. The fear is palpable: if a company launches in a lower-price market first, that initial price point could be referenced by larger, more lucrative markets, effectively capping the drug’s global revenue potential. This forces companies to weigh the immediate benefits of early access in smaller markets against the long-term strategic imperative of maximizing global revenue through optimal pricing. This can lead to delays in launching in certain countries, or even outright market withdrawals.
n
The Tough Choice: Withholding Access in Lower-Value Markets
n
Perhaps the most troubling implication highlighted by the survey is the willingness of some executives to opt not to launch their high-priced, specialty products at all in certain markets. This decision is not taken lightly but is seen as a necessary evil to protect the overall global commercial viability of a product. If the perceived "value" of a market (in terms of pricing potential, patient population size, and reimbursement environment) does not justify the investment and the potential negative impact on global pricing, companies are increasingly choosing to bypass it entirely.
This strategic retreat carries significant ethical and societal implications. While it may protect a company’s financial interests, it inevitably restricts patient access to potentially life-saving or life-improving therapies in those excluded regions. This creates a growing disparity in access to innovative medicines, exacerbating health inequalities between wealthier nations and those with more constrained healthcare budgets. The survey implicitly challenges the industry to balance commercial imperatives with its broader societal responsibilities.
The Evolving Landscape of Research and Development
The ripple effects of these policy shifts extend far beyond commercial strategies, profoundly influencing the very design and execution of pharmaceutical research and development. The quest for market access and optimal pricing is now dictating decisions at much earlier stages of drug development.
R&D Endpoints and Early Evidence Generation
As launch sequencing becomes a critical strategic consideration, companies are now asking fundamental questions about their clinical trial design: "Should the markets we plan to enter influence the endpoint we use in our studies?" and "How early should we generate that evidence?" This represents a significant departure from a purely scientific approach, where endpoints were primarily chosen based on biological plausibility and clinical significance. Now, the needs of HTA bodies, payers, and market access teams are directly informing trial design.
For instance, if a key market prioritizes a specific quality-of-life outcome or a direct comparator study, companies might design their trials to include those endpoints, even if they weren’t the primary scientific focus initially. This also means a push for earlier generation of market access-relevant evidence, potentially integrating health economics and outcomes research (HEOR) into earlier phases of clinical development.
The Real-World Evidence Imperative
The demand for robust data packages has intensified, with real-world evidence (RWE) emerging as a crucial component. While randomized controlled trials (RCTs) remain the gold standard for regulatory approval, key players in market access – health systems and payers – are increasingly seeking evidence beyond the controlled environment of a trial.
"Companies are viewing evidence generation as increasingly crucial in the post-marketing setting due to its potential to confirm a drug’s economic, clinical and patient-centric value past findings in a controlled trial environment," the report states. RWE, derived from electronic health records, claims data, patient registries, and other sources, offers insights into how a drug performs in diverse patient populations under routine clinical practice. This data is invaluable for:
- Confirming Effectiveness: Demonstrating real-world effectiveness and safety.
- Cost-Effectiveness: Providing data for pharmacoeconomic models to justify pricing.
- Comparative Efficacy: Showing how a drug performs against the current standard of care in a real-world setting, which is often a key criterion for reimbursement.
- Patient-Centric Value: Highlighting improvements in quality of life or patient-reported outcomes in diverse patient groups.
The strategic integration of RWE generation into post-marketing surveillance and lifecycle management is no longer optional but a critical component of market access success.
Strategic Indication Sequencing: Beyond the "Pipeline-in-a-Product"
The concept of "pipeline-in-a-product," where a single asset is developed for multiple indications, is also undergoing re-evaluation. While still attractive, the sequencing of these indications is becoming far more deliberate and commercially driven.
For "pipeline-in-a-product" assets, executives believe that "indication sequencing is becoming more deliberate, with the order of clinical activity prioritisation depending on policy changes in the focal market, as well as its downstream impact on commercial value." This means that companies might prioritize an indication that promises a higher price tag or easier market access outside the US, even if it targets a smaller patient population, over a broader indication with more available therapies and potentially more challenging pricing negotiations. This commercial calculus directly influences the allocation of R&D resources and the strategic roadmap for an asset.
Rethinking the Blockbuster Model: Niche Dominance?
The long-standing aspiration for multi-indication blockbusters, drugs that treat numerous conditions across vast patient populations, is also being questioned. Some executives are noting that smaller patient populations, particularly in rare diseases or highly stratified conditions, could offer stronger differential value. This differential value, underpinned by a clear unmet need and a highly targeted mechanism of action, could potentially pave the way to justify more premium pricing.
This perspective suggests a potential shift towards a more focused R&D strategy, where the pursuit of niche, high-value indications might take precedence over broad, generalist applications. While the blockbuster model isn’t entirely dead, its sustainability in the current policy environment is under scrutiny, leading to a renewed appreciation for therapies that offer profound, demonstrable value to specific, well-defined patient groups.
Broader Implications and Future Trajectories
The strategic shifts identified by the Numerof & Associates survey have far-reaching implications, extending beyond the balance sheets of pharmaceutical companies to touch patients, healthcare systems, and the very future of medical innovation.
Patient Access: A Growing Divide?
The most direct and concerning implication is the potential for a growing divide in patient access to innovative therapies. If pharmaceutical companies increasingly opt out of launching in lower-value markets, patients in those regions will be deprived of potentially life-changing treatments. This raises profound ethical questions about global health equity and the responsibility of innovators to serve all populations, not just the most profitable ones. Healthcare systems in these "excluded" markets will face the challenge of providing access to cutting-edge medicine without the direct involvement of the original manufacturers, potentially leading to reliance on generics, biosimilars, or delayed access.
Innovation at a Crossroads
The new policy environment could also impact the trajectory of pharmaceutical innovation itself. If the commercial viability of certain therapies in specific markets becomes increasingly tenuous, will companies reduce investment in those areas? This could particularly affect R&D for diseases prevalent in lower-income countries or for indications where the patient population is small and the return on investment is less clear. While policies like the EU Pharmaceutical Package aim to incentivize innovation for unmet needs, the overall commercial pressures could paradoxically steer investment towards high-income, high-reimbursement markets, potentially creating innovation gaps elsewhere.
The Economic Ripple Effect
The economic impact of these shifts is multifaceted. For pharmaceutical companies, it means navigating increased complexity, higher market access hurdles, and potentially constrained revenue growth in a globally interconnected pricing environment. For healthcare systems, it means intensifying pressure on negotiations, potentially leading to wider price disparities globally, and a constant struggle to secure innovative therapies within budget constraints. National pharmaceutical industries in countries that are deemed "lower-value" might also suffer from reduced investment and a weaker pipeline of new drugs.
Navigating the New Normal: A Call for Agility
The overarching conclusion from Numerof & Associates is clear: the pharmaceutical sector is undergoing a period of rapid evolution, and companies that fail to adapt their approach risk falling behind. The new normal demands not just strategic foresight but also fundamental changes in organizational structure and operational efficiency.
The Mandate for Organizational Transformation
At the heart of successful adaptation lies a commitment to organizational efficiency and agility. Companies must break down internal silos between R&D, commercial, market access, and regulatory teams to foster integrated decision-making. Data-driven insights must guide every step, from early-stage research to post-marketing evidence generation. This requires investing in robust data analytics capabilities, fostering a culture of cross-functional collaboration, and empowering teams to make rapid, informed decisions in a dynamic environment. The traditional hierarchical structures may need to be flattened to enable quicker responses to policy changes and market feedback.
Collaboration and New Business Models
In this complex environment, collaboration may become an even more critical strategic lever. Partnerships with academic institutions, contract research organizations (CROs), patient advocacy groups, and even competitor companies (in non-competitive areas like RWE generation standards) could help share risks and pool resources. Furthermore, the industry may need to explore new business models, moving beyond traditional fee-for-service pricing to embrace value-based agreements, risk-sharing models, or outcomes-based contracting, particularly in markets where upfront premium pricing is unfeasible. These innovative models could offer pathways to ensuring patient access while demonstrating the real-world value of therapies.
Conclusion: A New Era of Strategic Imperatives
The Numerof & Associates survey serves as a powerful wake-up call for the pharmaceutical industry. The confluence of evolving US and European policies, coupled with increasing scrutiny on clinical and economic value, has created a global ecosystem where strategic decisions must be made with an unprecedented level of foresight and interconnectedness. The era of easy market entry and isolated pricing is over. In its place, a new normal has emerged, demanding organizational agility, a deep understanding of global market dynamics, and a renewed commitment to demonstrating the holistic value of pharmaceutical innovation. For companies to thrive, and crucially, for patients worldwide to benefit from medical advancements, adapting to this new strategic imperative is not merely an option, but an absolute necessity.
